SBIR/STTR Research Award

Nanocapsule-mediated topical delivery of VLP-generating Dengue DNA vaccine

Award identifier a92a953ef9d3b3a0280bce79d1717c9812ec6bcc1e39a807f1149101608d5395Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,051

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VIVID TECHNOLOGIES INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
DP9ZTZNNGDE7
Solicitation number
PA12-088
Topic code
NIGMS

Research abstract

DESCRIPTION (provided by applicant): We synthesized a recombinant version of Mimivirus (MV) DNA topoisomerase 1B protein possessing an unusual 5'OH ligation activity (MV-ligase). This permits a novel type of probe for the detection of apoptotic cell clearance. In this project w will develop such new fluorescent probes for in situ research. The probes will visualize only those active phagocytic cells of any lineage (professional, amateur phagocytes or surrounding tissue cells) which engulf and digest apoptotic cell DNA. At the subcellular level, the probes will be the first specific markers of activated phagolysosomes - cellular organelles performing the actual phagocytic degradation of apoptotic cell corpses. Although the phagocytic phase is critical for efficient execution of apoptosis, there are currently no in situ probes specific for phagolysosomes digesting apoptotic cells. The project will close this technological gap and will provide a useful molecular tool. It will create an advantageous product withwide applicability in studies of pathologies where clearance of dying cells is essential, such as cancers, inflammation, infection and auto-immune disorders. The Specific Aims of the proposal are: 1) to develop the MV-ligase-based probes that will selectively label phagolysosomes of the cells that engulfed apoptotic nuclei and to test the probes using in vitro models. 2) To develop the first in situ assay for targeted detection of apoptotic cell clearance in tissue sections and to test and optimize its sensitivity, specificity and applicability in several apoptotic models. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposed project will result in the development of a new nano-scale technology for the needs of medical diagnostics and pathology. The technology will advance molecular imaging and will provide new enabling tools for molecular pathology and cell biology. It will allow precise evaluation of the effects of therapy in diseases such as various cancers, as well as stroke and Alzheimer's disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2007–2021). Reported award amounts total $1,557,288. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.